oxford-biotech
(3)
T-Cypher Bio
T-Cypher Bio is an Oxford, UK biotechnology company building a pipeline of TCR (T cell receptor) therapeutics for solid tumours and immune-mediated diseases. Spun out of Orbit Discovery in 2021 on technology licensed from the University of Oxford, it pairs a high-throughput, functional bead-display platform with immunopeptidomics, AI and bioinformatics to deconvolute vast T cell repertoires, find disease-specific targets, and identify potent, target-specific TCRs.
Paul Scagnetti
Paul Scagnetti is the CEO of ONI (Oxford Nanoimaging), the Oxford spin-out behind the Nanoimager, the first desktop super-resolution microscope to see single molecules at 20 nanometer resolution. A mechanical engineer with a PhD from MIT and 25+ years in life sciences and instruments, he left a job he loved at Illumina in February 2023 to bet that making Nobel-grade imaging simple enough for any lab would change drug discovery. In January 2025 he shipped the Aplo Scope, which he calls the biggest launch in ONI's history.
Scott Peterson
Scott Peterson is the Chief Business Officer of T-Cypher Bio, an Oxford-based biotech building next-generation TCR therapeutics for solid tumors and autoimmune disease. A Harvard-trained PhD who started his career at the lab bench as a medicinal chemist at Merck, he crossed over to the deal side and spent two decades shaping pipelines and partnerships at Intarcia, Spero, and Dewpoint Therapeutics before taking the commercial helm at T-Cypher. He is the rare dealmaker who can read both a term sheet and a reaction mechanism.